A systematic review of patient-derived tumor organoids generation from malignant effusions

Sofie Seghers,Maxim Le Compte,Jeroen M.H. Hendriks,Paul Van Schil,Annelies Janssens,Reinier Wener,Niels Komen,Hans Prenen,Christophe Deben
DOI: https://doi.org/10.1016/j.critrevonc.2024.104285
IF: 6.625
2024-02-14
Critical Reviews in Oncology/Hematology
Abstract:This review assesses the possibility of utilizing malignant effusions (MEs) for generating patient-derived tumor organoids (PDTOs). Obtained through minimally invasive procedures MEs broaden the spectrum of organoid sources beyond resection specimens and tissue biopsies. A systematic search yielded 11 articles, detailing the successful generation of 190 ME-PDTOs (122 pleural effusions, 54 malignant ascites). Success rates ranged from 33% to 100%, with an average of 84% and median of 92%. A broad and easily applicable array of techniques can be employed, encompassing diverse collection methods, variable centrifugation speeds, and the inclusion of approaches like RBC lysis buffer or centrifuged ME supernatants supplementation, enhancing the versatility and accessibility of the methodology. ME-PDTOs were found to recapitulate primary tumor characteristics and were primarily used for drug screening applications. Thus, MEs are a reliable source for developing PDTOs, emphasizing the need for further research to maximize their potential, validate usage, and refine culturing processes.
oncology,hematology
What problem does this paper attempt to address?